Fractyl Health (GUTS) Net Cash Flow (2023 - 2026)
Fractyl Health's (GUTS) quarterly Net Cash Flow came in at -$18.4 million in Q1 2026, up 27.54% YoY from -$14.4 million in Q1 2025, and down 573.14% on a QoQ basis from $3.9 million in Q4 2025.
Fractyl Health (GUTS) Net Cash Flow (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Net Cash Flow data on file, last reported at -$18.4 million in Q1 2026.
- Quarterly Net Cash Flow rose 27.54% year-over-year to -$18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (up 126.44% YoY) and the FY2025 annual result came in at $14.1 million, down 58.53% from the prior year.
- Net Cash Flow fell to -$18.4 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $88.2 million in Q1 2024 to a low of -$25.4 million in Q1 2025.
- A 4-year average of $1.1 million and a median of -$11.7 million in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 1021.77% in 2024, down 207.67% in 2024.
- Tracing GUTS's Net Cash Flow over 4 years: stood at -$11.3 million in 2023, then sank by 52.33% to -$17.2 million in 2024, then surged by 122.58% to $3.9 million in 2025, then plunged by 573.14% to -$18.4 million in 2026.
- The last three Net Cash Flow figures came in at -$18.4 million (Q1 2026), $3.9 million (Q4 2025), and $55.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 225.59 Mn |
| 10 | Fractyl Health | 125.70 Mn | 125.70 Mn | - | -16.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.03 Mn |
| Jun 30, 2026 | -16.03 Mn |
| Mar 31, 2026 | -18.37 Mn |
| Mar 31, 2026 | -18.37 Mn |
| Dec 31, 2025 | 3.88 Mn |
| Dec 31, 2025 | 3.88 Mn |
| Sep 30, 2025 | 55.37 Mn |
| Sep 30, 2025 | 55.37 Mn |
| Jun 30, 2025 | -19.82 Mn |
| Jun 30, 2025 | -19.82 Mn |
| Mar 31, 2025 | -25.36 Mn |
| Mar 31, 2025 | -25.36 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Sep 30, 2024 | -18.09 Mn |
| Sep 30, 2024 | -18.09 Mn |
| Jun 30, 2024 | -19.00 Mn |
| Jun 30, 2024 | -19.00 Mn |
| Mar 31, 2024 | 88.23 Mn |
| Mar 31, 2024 | 88.23 Mn |